Antiretroviral Therapy With Twice-Daily Dolutegravir Coadministered With Rifampicin Safe, Effective In Children With HIV-Associated TB, Study Demonstrates

September 01, 2022

Infectious Disease Advisor (8/31, Paridon) reports “antiretroviral therapy with twice-daily dolutegravir coadministered with rifampicin was found to be safe and overcame the enzyme-inducing effects of rifampicin in children with HIV-associated tuberculosi...